Europe Stem Cell Market Forecast 2022-2030KEY FINDINGS
The Europe stem cell market is set to grow with a CAGR of 8.60% over the forecast period of 2022 to 2030. The region’s market growth is strengthened by the rise in product releases, the increasing incidence of target conditions, the surge in awareness about stem cell-based therapies for different hair and skin disorders, and strategic initiatives like collaborations and agreements.
MARKET INSIGHTS
The Europe stem cell market growth study comprises the evaluation of the United Kingdom, Poland, Italy, France, Belgium, Germany, and Rest of Europe. As per the World Population Ageing report published in 2019, France had 13.28 million people aged 65 years and over. While this number is estimated to reach 16.09 million by 2030, the stem cell market in France is projected to witness substantial growth over the upcoming years, owing to the surge in the geriatric population.
On the other hand, given the rising number of chronic diseases in Italy, investments in research and development for developing effective treatments and clinical trials for stem cell therapy are anticipated to increase significantly. As per the estimations issued by AIRTUM 2020, around 377,000 new cases of malignant tumors were diagnosed in Italy, including 182,000 and 195,000 in women and men, respectively. Furthermore, the COVID-19 pandemic is one of the key factors driving the market demand in Italy. As a result, these factors are set to facilitate the Europe stem cell market growth during the forecast period.
COMPETITIVE INSIGHTS
Some of the main firms operating in the market are Qiagen, Smith+Nephew PLC, Merck KGaA (Sigma Aldrich), etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Surging Demand For Stem Cells In Regenerative Medicine
- 3.1.2. Growing R&D Investments In Stem Cell Therapies & Research
- 3.1.3. Rising Awareness About Umbilical Cord Stem Cells
- 3.1.4. Reduced Risk Of Tissue Rejection In Transplants
- 3.2. Key Restraints
- 3.2.1. Absence Of A Well-defined Regulatory Framework For Stem Cell Therapy
- 3.2.2. High Costs Associated With Stem Cell Procedures
- 3.2.3. Ethical Issues And Social Complexities
- 3.2.4. Less Responsiveness In Developed Economies
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Stem Cell Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.7.1. Price
- 4.7.2. Efficacy
- 4.7.3. Application And Effectiveness
- 4.7.4. Accuracy
- 4.8. Regulatory Framework
- 5. Market By Therapeutic Application
- 5.1. Orthopedic Treatments
- 5.2. Injuries & Wounds
- 5.3. Oncology Disorders
- 5.4. Cardiovascular Disorders
- 5.5. Neurological Disorders
- 5.6. Diabetes
- 5.7. Other Therapeutic Applications
- 6. Market By Product
- 6.1. Adult Stem Cell
- 6.1.1. Hematopoietic Stem Cell
- 6.1.2. Neural Stem Cell
- 6.1.3. Umbilical Cord Stem Cell
- 6.1.4. Mesenchymal Stem Cell
- 6.1.5. Dental Stem Cell
- 6.2. Human Embryonic Stem Cell
- 6.3. Pluripotent
- 6.4. Mouse/Rat Neural
- 7. Market By Technology
- 7.1. Cell Acquisition
- 7.1.1. Bone Marrow Harvest
- 7.1.2. Umbilical Cord
- 7.1.3. Apheresis
- 7.2. Cell Production
- 7.2.1. Therapeutic Cloning
- 7.2.2. In Vitro Fertilization (Ivf)
- 7.2.3. Cell Culture
- 7.2.4. Isolation
- 7.3. Cryopreservation
- 7.4. Expansion & Sub-culture
- 8. Market By Application
- 8.1. Regenerative Medicine
- 8.2. Drug Discovery And Development
- 9. Market By Treatment Type
- 9.1. Allogeneic Stem Cell Therapy
- 9.2. Autologic Stem Cell Therapy
- 9.3. Syngeneic Stem Cell Therapy
- 10. Geographical Analysis
- 10.1. Europe
- 10.1.1. Market Size & Estimates
- 10.1.2. Key Growth Enablers
- 10.1.3. Key Challenges
- 10.1.4. Key Players
- 10.1.5. Country Analysis
- 10.1.5.1. United Kingdom
- 10.1.5.2. Germany
- 10.1.5.3. France
- 10.1.5.4. Italy
- 10.1.5.5. Belgium
- 10.1.5.6. Poland
- 10.1.5.7. Rest Of Europe
- 11. Competitive Landscape
- 11.1. Key Strategic Developments
- 11.1.1. Acquisitions
- 11.1.2. Partnerships
- 11.2. Company Profiles
- 11.2.1. Allcells Llc
- 11.2.2. Becton, Dickinson And Company (Bd)
- 11.2.3. Corning Inc
- 11.2.4. Ge Healthcare
- 11.2.5. International Stem Cell Corporation
- 11.2.6. Lorem Cytori Inc
- 11.2.7. Merck Kgaa (Sigma Aldrich)
- 11.2.8. Miltenyi Biotec
- 11.2.9. Pluri Inc
- 11.2.10. Qiagen
- 11.2.11. Smith+Nephew Plc
- 11.2.12. Stemcell Technologies Inc
- 11.2.13. Stryker Corporation
- 11.2.14. Takara Holdings Inc
- 11.2.15. Thermo Fisher Scientific Inc
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook